Use access key #2 to skip to page content.

MightyMaven's rating is .

  • Score: N/A
  • Accuracy: N/A

A player's rating indicates his percentile rank in CAPS. MightyMaven is outperforming % of all CAPS players. A player's score is the total percentage return of all his picks subtracting out the S&P. A player's accuracy is how often that player has made correct predictions.

To calculate a player's rating, we take 2/3 of his score percentile and 1/3 of his accuracy percentile. For further information, read the Player Ratings section of the Help page.

Average Pick Score is a player's total score divided by the total number of picks (active and closed). It represents the player's average return after subtracting out the market's performance.

Average Pick Rating is the average stock rating of a player's total picks. Underperform picks are flip-flopped, so a underperform call on a one-star stock is treated like an outperform call on a five-star stock. This rating reflects how closely your picks are aligned with CAPS ratings.

What's the deal with N/A?
You need to have at least seven active stocks in order to see your calculated accuracy and total score.

MightyMaven (< 20)

No Lucky Charms earned yet.

MightyMaven beat the market on Friday

Player Rating CAPS Rating

None

Rank: N/A
Score: N/A
Accuracy: N/A
Average Pick Score:
Average Pick Rating:
All-Time Best: APA +19.02
All-Time Worst: GSB -66.09

Score Comparison vs. MightyMaven

Player History

How are these stats calculated?

MightyMaven's Latest Blog Post

Recs

1

Aphria Produces Astounding Quarter, PE/G Ratio Reads Undervalued

July 21, 2017 – Comments (0) | RELATED TICKERS: ACBFF , TWMJF

Time to Test the Soundness of Another Writer

Refuse to be Spoonfed by Writers; Analyze Their Analysis for Soundness and Validity
Remember to always think actively when reading articles on how you should invest your money. Just because something is in print form does not make it sound or valid information. It doesn't matter if it has been published or not by an official news source because everywhere you look writers leave out pertinent facts all the time, and without pertinent facts, an investor is missing key bases for understanding if an investment is undervalued or overvalued. That can cause you to miss out on many great opportunities and it can cause you to continue on in a bad investment you should get out of. So don't let anyone spoonfeed you their investment advice and take an active role in critiquing their words. What got my motor running this morning was when I read a story about Aphria that it's PE was "Yikes" high and has a "frothy valuation". While there were a lot of positive points made in the 'article', the writer countered that with the so-called negatives of a high PE ratio. So let's look at how sound that advice was this morning.

Let's Look at Some Proper Context for Talking About PE Ratios
Aphria (APH.TO) (APHQF) According to Fidelity Investments and other webistes, Aphria's PE is 122.75 and their expected earnings growth rate is 333.33%. Do you see what I see? That means the PEG ratio is 122.75/333.33 = 0.3682536825368254. That's right, Aphria's PEG ratio is an extremely low 0.368. While some consider a PEG ratio of 1.0 to be basic fair value, one must look at the industry PEGs for a better indication. PEG value for the pharmaceutical industry is 76.39. What? Really? Yes, according to Fidelity. PEG ratio is PE ratio divided by G growth of earnings. So as a pharmaceutical company, Aprhis is growing enormously more than the industry rate, as the PEG ratios for each show us. Just to match it's stock price and PE ratio to its income growth rate so that it has a PEG ratio of 1.0 would require the stock price to multiply by 2.71 times.That's right. If the price TRIPLED, Aphria's PEG ratio would just be 1.0.  Multiplied out, 2.71 x $4.9099 = $13.33 per share. And that's not giving it the PEG ratio of the industry (a 76) but a PEG ratio of 1.0, matching the PE to the company's expected earnings growth. If you matched it to its historical growth rate, you would have to use a figure 3 times that amount and the price projection of fair value would be closer to $40.00. Using forward earnings is better at this stage as it provides a more conservative valuation of $13.33 that $40.00+-. With revenue growth at 143%, with their improved cost of goods sold, the earnings growth projection has strong support from the top line growth.That's hard for its closest competitors Aurora Cannabis and Canopy Growth to do.

Remember: Scary Buzzwords are not Proper Analysis and They Don't Take It's Place Either
So remember not to be fooled by analysts who claim a PE is crazy high. You must always check to see if it matches its earnings growth rate and if earnings is backed up by good growth in sales. A 200 PE could sound high, but if earnings growth is 400%, then the PE could have another 200 basis points to grow. And just as a PEG ratio can be below the growth rate, really, the other side of the coin is that a PEG ratio can also go ABOVE the growth rate, as is seen by the industry PEG of 76. So don't let any writers scare you out of an investment because of a PE that is higher than most PEs in the market. There's more to the story. If they are playing on your emotions, they like to use fear-evoking words like 'crazy', 'frothy' and 'yikes' to stoke the emotional content away from rational analysis. Check their so-called facts out and remember my admonition that statistics can be made to appear to say anything, and this is another example of that. PE is a statistical ratio. But PE by itself has no context to determine if it is relatively high or low. You cannot compare a PE of a company to the total market or to wrong industries because that's an apple to oranges or pears comparison, and better is an industry-specific comparison and best of all is comparing a company to itself, comparing its growth today versus its sales last year; or by its expected growth rate for the year compared to its current sales. I see that the writer in question did NOT make such a comparison. Beware of writers that leave out such pertinent information from their writing especially when leaving it out helps them make their case for or against investing in a particular stock. You can bet they left it out just for that reason. And leaving it out really is a disservice to you as a reader and investor because it can be really very misleading. Always question writers' motives and look for the proper context that they may have left out. With PE discussions, always look at growth along with it.  [more]

Blog Archive

2017
July (4)

MightyMaven's Stock Picks

Results 1 - 2 of 2  

picks per page. CHANGE Expand All Pitches

Top
Pick
Start
Date
TickerCAPS RatingCallTime FrameStart PriceToday (Change)Stock
Gain
Index
Gain
ScorePitch
07/14/17 GSB Outperform 5Y $5.31 $5.06
( -3.44%)
-4.71%+0.50%-5.21 Toggle the visibility of 60-Second Pitch and replies
07/06/17 XXII Outperform 5Y $1.69 $1.60
( -1.84%)
-5.27%+2.03%-7.30 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 2 of 2  

Featured Broker Partners